Researchers report progress in advanced pancreatic cancer by targeting a biological mechanism linked to aggressive tumour behaviour. According to The Conversation (France), about 97% of patients diagnosed with advanced-stage pancreatic cancer die within five years, highlighting the need for new treatments. The reported study focuses on a drug strategy that aims at a specific protein considered difficult or “impossible to block.” The researchers describe how the medication is designed to interfere with the pathway that enables these tumours to resist existing therapies. They state that the approach can significantly improve outcomes, including doubling survival rates compared with prior expectations described for this stage of disease. The coverage emphasizes the shift from general treatment methods toward therapies that act on defined molecular targets. It does not cite a broader set of comparative results in the provided excerpts, but the central message across the source text is consistent: a targeted drug approach against a challenging protein mechanism shows promise in extending survival for patients with advanced pancreatic cancer.